Bayer: prostate cancer drug extends survival

(CercleFinance.com) - German pharma group Bayer's investigational drug darolutamide significantly extended the lives of men with prostate cancer compared to placebo, according to new data from a late-stage study presented on Friday.


Results from a Phase III trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a 'statistically significant improvement' in metastasis-free survival with the investigational drug darolutamide plus androgen deprivation therapycompared to placebo, Bayer said.

The median survival was 40.4 months in the darolutamide arm compared with 18.4 months for the placebo arm.

Bayer now plans to discuss the data from the trial with health authorities regarding the submission of new drug applications. Bayer has alredy been granted a fast track designation by the US FDA.

Copyright (c) 2019 CercleFinance.com. All rights reserved.